506 related articles for article (PubMed ID: 33728735)
21. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study.
Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J
J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328
[TBL] [Abstract][Full Text] [Related]
22. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP; Egyed M; Jurczak W; Skarbnik A; Pagel JM; Flinn IW; Kamdar M; Munir T; Walewska R; Corbett G; Fogliatto LM; Herishanu Y; Banerji V; Coutre S; Follows G; Walker P; Karlsson K; Ghia P; Janssens A; Cymbalista F; Woyach JA; Salles G; Wierda WG; Izumi R; Munugalavadla V; Patel P; Wang MH; Wong S; Byrd JC
Lancet; 2020 Apr; 395(10232):1278-1291. PubMed ID: 32305093
[TBL] [Abstract][Full Text] [Related]
23. Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma.
Song Y; Zhou K; Yang S; Hu J; Zou D; Gao S; Pan L; Wang T; Yang H; Zhang H; Zhou D; Ji J; Xu W; Feng R; Jin J; Lv F; Huang H; Fan X; Xu S; Zhu J
Invest New Drugs; 2023 Aug; 41(4):606-616. PubMed ID: 37420136
[TBL] [Abstract][Full Text] [Related]
24. A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma.
Strati P; Coleman M; Champion R; Ma S; Patti C; Levy MY; Lossos IS; Geethakumari PR; Lam S; Calvo R; Higgins K; Budde LE
Br J Haematol; 2022 Oct; 199(1):76-85. PubMed ID: 35861370
[TBL] [Abstract][Full Text] [Related]
25. Acalabrutinib and its use in the treatment of chronic lymphocytic leukemia.
Egyed M; Lueff S; Borbely J; Illes A
Future Oncol; 2022 Mar; 18(7):755-769. PubMed ID: 35139644
[TBL] [Abstract][Full Text] [Related]
26. Acalabrutinib: First Global Approval.
Markham A; Dhillon S
Drugs; 2018 Jan; 78(1):139-145. PubMed ID: 29209955
[TBL] [Abstract][Full Text] [Related]
27. Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.
Munakata W; Ando K; Hatake K; Fukuhara N; Kinoshita T; Fukuhara S; Shirasugi Y; Yokoyama M; Ichikawa S; Ohmachi K; Gion N; Aoi A; Tobinai K
Cancer Sci; 2019 May; 110(5):1686-1694. PubMed ID: 30815927
[TBL] [Abstract][Full Text] [Related]
28. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.
Byrd JC; Hillmen P; Ghia P; Kater AP; Chanan-Khan A; Furman RR; O'Brien S; Yenerel MN; Illés A; Kay N; Garcia-Marco JA; Mato A; Pinilla-Ibarz J; Seymour JF; Lepretre S; Stilgenbauer S; Robak T; Rothbaum W; Izumi R; Hamdy A; Patel P; Higgins K; Sohoni S; Jurczak W
J Clin Oncol; 2021 Nov; 39(31):3441-3452. PubMed ID: 34310172
[TBL] [Abstract][Full Text] [Related]
29. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
30. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
31. Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Tam CS; Trotman J; Opat S; Burger JA; Cull G; Gottlieb D; Harrup R; Johnston PB; Marlton P; Munoz J; Seymour JF; Simpson D; Tedeschi A; Elstrom R; Yu Y; Tang Z; Han L; Huang J; Novotny W; Wang L; Roberts AW
Blood; 2019 Sep; 134(11):851-859. PubMed ID: 31340982
[TBL] [Abstract][Full Text] [Related]
32. A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Walter HS; Rule SA; Dyer MJ; Karlin L; Jones C; Cazin B; Quittet P; Shah N; Hutchinson CV; Honda H; Duffy K; Birkett J; Jamieson V; Courtenay-Luck N; Yoshizawa T; Sharpe J; Ohno T; Abe S; Nishimura A; Cartron G; Morschhauser F; Fegan C; Salles G
Blood; 2016 Jan; 127(4):411-9. PubMed ID: 26542378
[TBL] [Abstract][Full Text] [Related]
33. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
34. Acalabrutinib for adults with mantle cell lymphoma.
Jurczak W; Długosz-Danecka M; Wang M
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):179-187. PubMed ID: 30638402
[TBL] [Abstract][Full Text] [Related]
35. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia.
Rogers KA; Thompson PA; Allan JN; Coleman M; Sharman JP; Cheson BD; Jones D; Izumi R; Frigault MM; Quah C; Raman RK; Patel P; Wang MH; Kipps TJ
Haematologica; 2021 Sep; 106(9):2364-2373. PubMed ID: 33730844
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials.
Wang Z; Zhou H; Xu J; Wang J; Niu T
Front Immunol; 2022; 13():1070660. PubMed ID: 36685572
[TBL] [Abstract][Full Text] [Related]
37. Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
Nierman P
Clin J Oncol Nurs; 2021 Dec; 25(6):687-696. PubMed ID: 34800101
[TBL] [Abstract][Full Text] [Related]
38. Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
Makita S; Ota S; Mishima Y; Usuki K; Ennishi D; Yanada M; Fukuhara N; Yamamoto R; Takamine A; Nohara G; Izutsu K
Int J Hematol; 2024 Feb; 119(2):156-163. PubMed ID: 38150138
[TBL] [Abstract][Full Text] [Related]
39. Real-world experience of Australian and New Zealand patients with chronic lymphocytic leukemia and mantle cell lymphoma accessing ibrutinib through a Named Patient Program.
Mulligan SP; Opat S; Cheah CY; Kuss B; Hertzberg M; Marlton P; Poplar S; Puig A; McGeachie M; Weinkove R; Tam CS
Leuk Lymphoma; 2023 Feb; 64(2):312-318. PubMed ID: 36423351
[TBL] [Abstract][Full Text] [Related]
40. The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
Seftel MD; Kuruvilla J; Kouroukis T; Banerji V; Fraser G; Crump M; Kumar R; Chalchal HI; Salim M; Laister RC; Crocker S; Gibson SB; Toguchi M; Lyons JF; Xu H; Powers J; Sederias J; Seymour L; Hay AE
Leuk Lymphoma; 2017 Jun; 58(6):1358-1365. PubMed ID: 27750483
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
